Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV

Southern African Journal of HIV Medicine
Paula MunderiYvon van Delft

Abstract

In low- and middle-income countries (LMICs), a substantial unmet need for affordable single-tablet regimen (STR) options remains. Rilpivirine (RPV, TMC278) is formulated in a low-cost STR with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). Switching at Low HIV-1 RNA into Fixed Dose Combinations (SALIF) compared RPV with efavirenz (EFV), both as STRs with TDF and FTC, in maintaining virologic suppression. SALIF was a phase 3b, randomised, open-label, non-inferiority study in virologically suppressed adults (HIV-1 RNA < 50 copies/mL) on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line antiretroviral therapy (ART) in Cameroon, Kenya, Senegal, South Africa, Uganda and Thailand. Patients (N = 426), stratified by NNRTI use, were randomised 1:1 to receive TDF/FTC/RPV (300/200/25 mg qd) or TDF/FTC/EFV (300/200/600 mg qd). Primary endpoint was proportion of patients with virologic suppression (HIV-1 RNA < 400 copies/mL) at week 48 (intent-to-treat, modified Food and Drug Administration Snapshot, 10% non-inferiority margin). Patients received TDF/FTC/RPV (n = 213) or TDF/FTC/EFV (n = 211). At week 48, virologic suppression was maintained in 200/213 (93.9%) patients in the RPV arm and 203/211 (96.2%) i...Continue Reading

References

Jan 5, 2010·Current Opinion in HIV and AIDS·Nathan Ford, Alexandra Calmy
May 17, 2013·Bulletin of the World Health Organization·James H McMahonMichael R Jordan
Nov 21, 2013·Enfermedades infecciosas y microbiología clínica·Pere Domingo, Esteban Ribera
Apr 25, 2015·AIDS Research and Therapy·Weerawat ManosuthiUNKNOWN Adults and Adolescents Committee of the Thai National HIV Guidelines Working Group
Jun 20, 2015·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Carmela PinnettiMauro Zaccarelli
Nov 1, 2015·The Journal of Antimicrobial Chemotherapy·Ujjwal NeogiAnders Sönnerborg
Dec 15, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rochelle P WalenskyA David Paltiel
Feb 27, 2016·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Anna H TranUNKNOWN IMPAACT P1026s Protocol Team
Jul 13, 2016·JAMA : the Journal of the American Medical Association·Huldrych F GünthardPaul A Volberding
Jul 8, 2017·BMC Infectious Diseases·Delphine SculierUNKNOWN Swiss HIV Cohort Study
Mar 24, 2018·Southern African Journal of HIV Medicine·Graeme MeintjesFrancois Venter

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.

© 2021 Meta ULC. All rights reserved